REGENXBIO plans top-line RGX-202 Duchenne data release in early Q2 2026 while advancing toward 2027 commercial launch [Seeking Alpha]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Seeking Alpha
Curran Simpson, President and CEO, highlighted strong momentum in late-stage gene therapy programs, emphasizing the progress of RGX-202 for Duchenne muscular dystrophy, RGX-121 for MPS II (Hunter syndrome), and retinal franchise programs. Simpson stated, "We are very pleased Quick Insights REGENXBIO reports completed AFFINITY DUCHENNE enrollment for RGX-202, anticipates RGX-202 pivotal data and BLA submission in 2026, and expects RGX-121 FDA approval by early next year with commercial supply ready. REGENXBIO ended Q3 2025 with $302 million in cash, projecting this to fund operations into early 2027, with additional nondilutive financing and milestones potentially extending the runway. Analysts focused on regulatory risks, trial enrollment, manufacturing scale, and possible label warnings. Management emphasized strong safety results, scalable manufacturing, and contingency plans for nondilutive funding to address these concerns. More Trending News
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Regenxbio files $300M mixed shelf offering [Seeking Alpha]Seeking Alpha
- REGENXBIO to Participate in Upcoming Investor Conference [Yahoo! Finance]Yahoo! Finance
- REGENXBIO to Participate in Upcoming Investor ConferencePR Newswire
- REGENXBIO (NASDAQ:RGNX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RGNX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> MarketBeat
RGNX
Earnings
- 11/6/25 - Beat
RGNX
Sec Filings
- 11/26/25 - Form S-3
- 11/6/25 - Form 8-K
- 11/6/25 - Form 10-Q
- RGNX's page on the SEC website